All lobbying filings

E3 STRATEGIC CONSULTING GROUP

Lobbying for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Association

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Virginia · House · Senate · $60,000.00 income · posted Jul 9, 2026

Official filing document

Bills named in this filing 6

S 1040
Drug Competition Enhancement Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 4317
PBM Reform Act of 2025
HR 5256
340B ACCESS Act
S 3345
PBM Price Transparency and Accountability Act
S 2658
Medication Affordability and Patent Integrity Act

Lobbying activity 1

Pharmacy

Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.